Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has sold its radiation-detection device business to Devicor Medical Products in a deal that could reach a value as high as $50 million. Devicor, a Wisconsin-based holding company backed by Chicago private equity firm GTCR Golder Rauner, has agreed to buy Neoprobe’s device business for $30 million in cash […]
Cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) plans to file for U.S. regulatory approval of its cancer-tracing agent Lymphoseek next quarter. CEO David Bupp confirmed on a conference call with investors that the Dublin, Ohio company during the second quarter would file a New Drug Application (NDA) for the tracing agent with the U.S. Food and […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Neoprobe (NYSE Amex:NEOP) has reached an agreement to license imaging technology from Naviscan. The combined technology could produce images that allow surgeons to more precisely target cancerous lymph nodes for removal.
Neoprobe Corp. (OTCBB:NEOP) continues to take steps down the regulatory path aimed at restarting development efforts for its RIGScan cancer-detecting technology.
Neoprobe Corp. (OTCBB:NEOP) has hired a biotechnology and pharmaceuticals industry veteran as its chief development officer. Mark Pykett, 46, steps into the role, which calls for him to assist the company with its product and business development, partnering and investor relations efforts.
Neoprobe Corp.'s (OTCBB:NEOP) third-quarter loss narrowed, but more importantly, the company remains on track to file for regulatory approval of its cancer-detecting drug Lymphoseek early next year.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Neoprobe Corp. (OTCBB:NEOP) has raised $6 million by selling 3.2 million shares of its common stock to unidentified institutional investors.
Neoprobe Corp. (OTCBB:NEOP) has taken a step forward in the often-lengthy regulation process as it lays plans to commercialize its cancer-detection drug, RIGScan.
A delay in the regulatory approval process for Neoprobe Corp.'s (OTCBB:NEOP) cancer drug could have the effect of helping the company increase the drug's price once it's commercialized.
Device and drugmaker Neoprobe Inc. (OTCBB: NEOP) has applied for listing on the NYSE: Amex market. The move would make the Dublin, Ohio, company more attractive to institutional investors and provide more liquidity for existing investors, according to a statement from the company. Neoprobe is currently traded on Nasdaq’s Over-The-Counter Bulletin Board. CEO David Bupp […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Updated 11:20 a.m., July 2, 2010. Neoprobe Corp. (OTCBB: NEOP) is closing in on that transformative moment when a company launches its first game-changing product. The Dubin, Ohio, company last week won a $1 million Ohio Third Frontier grant to speed additional development of its first commercial radiopharmaceutical — Lymphoseek, which is a tracing agent […]
Two new probe products helped Neoprobe Corp. narrow losses and boost revenue in 2009, but the unwinding of a complex financing deal cost the company $34 million in noncash charges. Neoprobe, which sells the GDS line of gamma detection devices used by cancer surgeons, reported a loss attributable to common stockholders of $353,638, or zero […]
The company has already received European regulatory approval for the proposed trial's design and is hoping to receive approval from the U.S. Food and Drug Administration sometime in the second quarter, according to Chief Financial Officer Brent Larson.
The company in recent months has made a series of adjustments -- both financial adjustments and through partnerships -- to advance its two drugs. In the case of Lymphoseek, it expects to file a new drug application with the U.S. Food and Drug Administration sometime in the next 18 months. A distribution deal with Cardinal Health could help Neoprobe quickly double its annual revenue if that drug is approved.
Neoprobe had told investors in June that the company would need a development partner for RIGScan, which was essentially dead after the FDA denied its application in 1997. But there has been renewed interest in recent years, and Neoprobe said it has had positive meetings with the European Medicines Agency and is awaiting guidance on a new application to the FDA.